New insight into immunosuppression and treatment of autoimmune diseases

Clinical and Experimental Rheumatology

Volumn 24, Issue SUPPL. 40, 2006, Pages

  Bohm M ^a   Luger, T A ^a   Schneider, M ^b   Schwarz, T ^c   Kuhn, Annegret ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

Autoimmune diseases; Immunosuppressive treatment; New biological agents; Photoimmunosuppression

Indexed keywords

ABATACEPT; ABETIMUS; ADALIMUMAB; ANTIINFLAMMATORY AGENT; ATLIZUMAB; BASILIXIMAB; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; DACLIZUMAB; EPRATUZUMAB; ETANERCEPT; GALIXIMAB; IDEC 114; IDEC 131; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INOLIMOMAB; INTERLEUKIN 10; INTERLEUKIN 4; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; RUPLIZUMAB; STEROID; TOSITUMOMAB; TSUKUBAENOLIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNE DISEASE; BIOTECHNOLOGY; CLINICAL TRIAL; DRUG BINDING; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HEMORRHAGIC COLITIS; HUMAN; HYPERTENSION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MOLECULAR MECHANICS; NEPHROTOXICITY; NONHUMAN; PHOTOTHERAPY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TREATMENT RESPONSE; TREMOR; ULTRAVIOLET RADIATION;

AUTOIMMUNE DISEASES; HUMANS; IMMUNOSUPPRESSION;

EID: 33645028068     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. KRIPKE ML: Immunology and photocarcinogenesis. J Am Acad Dermatol 1986; 14: 149-55.
2. TOEWS GB, BERGSTRESSER PR, STREILEIN JW: Epidermal Langerhans cell density determines whether contact hypersensitivity or unresponsiveness follows skin painting with DNFB. J Immunol 1980; 124: 445-53.
3. ULLRICH SE: Mechanisms involved in the systemic suppression of antigen-presenting cell function by UV irradiation. Keratinocyte-derived IL-10 modulates antigen-presenting cell function of splenic adherent cells. J Immunol 1994; 15 2: 3410-16.
4. ELMETS CA, BERGSTRESSER PR, TIGELAAR RE, WOOD PJ, STREILEIN JW: Analysis of the mechanism of unresponsiveness produced by haptens painted on skin exposed to low dose ultraviolet radiation. J Exp Med 1983; 158: 781-94.
5. SCHWARZ T: Regulatory T cells induced by ultraviolet radiation. Int Arch Allergol Immunol 2005; 137: 187-93.
6. SCHWARZ A, MAEDA A, WILD MK et al.: Ultraviolet radiation-induced regulatory T cells not only inhibit the induction but can suppress the effector phase of contact hypersensitivity. J Immunol 2004; 172: 1036-43.
7. KRIPKE ML, COX PA, ALAS LG, YAROSH DB: Pyrimidine dimers in DNA initiate systemic immunosuppression in UV-irradiated mice. Proc Natl Acad Sci USA 1992; 89: 7516-7520.
8. SCHWARZ A, STÄNDER S, BERNEBURG M et al.: Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair. Nat Cell Biol 2002; 4: 26-31.
9. SCHWARZ A, MAEDA A, KERNEBECK K, van STEEG H, BEISSERT S, SCHWARZ T: Prevention of UV radiation-induced immuno-suppression by IL-12 is dependent on DNA repair. J Exp Med 2005; 201:173-9.
10. MOODYCLIFFE AM, NGHIEM D, CLYDESDALE G, ULLRICH SE: Immune suppression and skin cancer development: regulation by NKT cells. Nat Immunol 2000; 1: 459-60.
11. DOSTAL C, TESAL V, RYCHLIK I et al.: Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus, a pilot study. Lupus 1998; 7: 29-36.
12. RUZICKA T, ASSMANN T, HOMEY B: Tacrolimus: the drug for the turn of the millennium? Arch Dermatol 1999; 135: 574-80.
13. KANEKURA T, YOSHII N, TERASAKI K, MIYOSHI H, KANZKI T: Efficaicy of topical tacrolimus for treating the malar rash of systemic lupus erythematosus. Br J Dermatol 2003; 148: 353-6.
14. WONG JM, ESDAILE JM: Methotrexate in systemic lupus erythematosus. Lupus 2005; 14:101-5.
15. HUGHES GRV, D'CRUZ D: Mycophenolate mofetil, an advance in the therapy of autoimmune disease. Lupus 2005; 14: S1.
16. CHAN TM, LI FK, TANG CS et al.: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2004; 350: 971-80.
17. PISONI CN, OBERMOSER G, CUADRADO MJ et al.: Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil. Clin Exp Rheumatol 2005; 23: 393-6.
18. PISONI CN, SANCHEZ FJ, KARIM Y: Mycophenolate mofetil in systemic lupus erythematosus, efficacy and tolerability in 86 patients. J Rheumatol 2005; 32: 1047-52.
19. ARMSTRONG DJ, WRIGHT SA, FINCH MB, TAGGART AJ, BELL AL: Active systemic lupus erythematosus successfully treated with rituximab and oral steroid. Clin Exp Rheumatol 2004; 22: 787-8.
20. SFIKAKIS PP, BOLETIS IN, LIONAKI S, FRAGIADAKI KG, INIOTAKI A, MOUTSOPOULOS HM: Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the costimulatory molecule CD40 ligand. Arthritis Rheum 2005; 52: 501-13.
21. ALARCÓN-SEGOVIA D, TUMLIN JA, FURIE RA et al.: LJP 394 for the prevention of renal flares in patients with systemic lupus erythematosus. Results from a randomised, doubleblind, placebo-controlled study. Arthritis Rheum 2004; 48: 442-54.
22. FELDMANN M, STEINMAN L: Design of effective immunotherapy for human autoimmunity. Nature 2005; 435: 612-9.
23. GOTTLIEB AB: Psoriasis: emerging therapeutic strategies. Nat Rev Drug Discov 2005; 4: 19-34.
24. RÜTTER A, LUGER TA: Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases. Carr Opin Investig Drugs 2002; 3: 713-9.
25. ARINGER M, GRANINGER W, STEINER G, SMOLEN JS: Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3161-9.
26. GOTTENBERG JE, GUILLEVIN L, LAMBOTTE O et al.: Tolerance and short term efficacy of rituximab in 43 patients with systemic antoimmune diseases. Ann Rheum Dis 2005; 64: 913-20.
27. SCHOTTELIUS AJ, MOLDAWER LL, DINARELLO CA, ASADULLAH K, STERRY W, EDWARDS CK: Biology of tumor necrosis factor-alpha - Implications for psoriasis. Exp Dermatol 2004; 13: 193-222.
28. NUMEROF RP, DINARELLO CA, ASADULLAH K: Cytokines as potential therapeutic targets for inflammatory skin diseases. Eur Cytokine Netw 2005; 16: 101-3.
29. TOBIN AM, KIRBY B: TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. BioDrugs 2005; 19: 47-57.
30. OSTENDORF B, IKING-KONERT C, KURZ K, JUNG G, SANDER O, SCHNEIDER M: Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 2005; 64: 630-3.
31. GHORESCHI K, THOMAS P, BREIT S et al.: Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat Med 2003; 9: 40-6.
32. KAUFFMAN CL, ARIA N, TOICHI E et al.: A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 2004; 123: 1037-44.
33. GOTTLIEB AB, KANG S, LINDEN KG et al.: Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunol 2004; 111: 28-37.
34. DAVIS JC JR, TOTORITIS MC, ROSENBERG J, SKLENAR TA, WOFSY D: Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001; 28: 95-101.
35. GENOVESE MC, BECKER JC, SCHIFF M et al.: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 53: 1114-23.
36. ROTHER RP, MOJCIK CF, McCROSKERY EW: Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus 2004; 13: 328-34.